Where Werewolf Therapeutics Stands With Analysts
Ratings for Werewolf Therapeutics (NASDAQ:HOWL) were provided by 7 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 4 | 3 | 0 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 1 | 1 | 0 | 0 | 0 |
| 2M Ago | 2 | 1 | 0 | 0 | 0 |
| 3M Ago | 0 | 1 | 0 | 0 | 0 |
In the assessment of 12-month price targets, analysts unveil insights for Werewolf Therapeutics, presenting an average target of $13.71, a high estimate of $15.00, and a low estimate of $12.00. Highlighting a 2.07% decrease, the current average has fallen from the previous average price target of $14.00.
Diving into Analyst Ratings: An In-Depth Exploration
In examining recent analyst actions, we gain insights into how financial experts perceive Werewolf Therapeutics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Andres Maldonado | HC Wainwright & Co. | Maintains | Buy | $15.00 | $15.00 |
| Reni Benjamin | JMP Securities | Maintains | Market Outperform | $12.00 | $12.00 |
| Andres Maldonado | HC Wainwright & Co. | Maintains | Buy | $15.00 | $15.00 |
| Andres Maldonado | HC Wainwright & Co. | Maintains | Buy | $15.00 | $15.00 |
| Reni Benjamin | JMP Securities | Maintains | Market Outperform | $12.00 | $12.00 |
| Andres Maldonado | HC Wainwright & Co. | Maintains | Buy | $15.00 | $15.00 |
| Reni Benjamin | JMP Securities | Announces | Market Outperform | $12.00 | - |
Key Insights:
- Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Werewolf Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Werewolf Therapeutics compared to the broader market.
- Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Werewolf Therapeutics's stock. This comparison reveals trends in analysts' expectations over time.
To gain a panoramic view of Werewolf Therapeutics's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
Stay up to date on Werewolf Therapeutics analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
About Werewolf Therapeutics
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.
Key Indicators: Werewolf Therapeutics's Financial Health
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Decline in Revenue: Over the 3 months period, Werewolf Therapeutics faced challenges, resulting in a decline of approximately -83.38% in revenue growth as of 31 March, 2024. This signifies a reduction in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -2182.35%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Werewolf Therapeutics's ROE stands out, surpassing industry averages. With an impressive ROE of -14.14%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Werewolf Therapeutics's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of -9.19%, the company showcases efficient use of assets and strong financial health.
Debt Management: Werewolf Therapeutics's debt-to-equity ratio is below the industry average. With a ratio of 0.44, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
Analyst Ratings: What Are They?
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.